Pharmaceuticals Ltd. on Saturday said it has launched antiviral drug under the brand name FabiFlu, for the treatment of patients with mild to moderate at a price of about Rs 103 per tablet. is the first oral favipiravir-approved medication in India for the treatment of it said in a statement. It is a prescription-based with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, said the drugmaker.News source- Bloomberg Quint #Glenmark #Favipiravir #Covid #FabiFlu #medication
ಪೋಸ್ಟ್ ಮಾಡಲಾಗಿದೆ: 20 Jun 2020 9:23 PM
